The Republic of Kazakhstan’s Ministry of Health has granted authorisation for Russia’s Sputnik M vaccine in adolescents aged 12 to 17 years, the Russian Direct Investment Fund (RDIF) reported.

With the latest development, Kazakhstan became the first nation outside Russia to grant authorisation to Sputnik M.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Gamaleya Center in Russia developed the vaccine specifically for use in adolescents.

A two-dose vaccine, Sputnik M is based on a safe human adenoviral vectors platform that has been extensively studied for more than three decades. 

As against the Sputnik V vaccine, Sputnik M has five times reduced concentration of viral particles for each dose.

In November last year, the Russian Ministry of Health registered the Sputnik M vaccine based on results from clinical trials that established the favourable safety and immunogenicity profile of the vaccine in adolescents. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Following inoculation with Sputnik M, no serious adverse events were reported in the trials. 

The latest findings are consistent with results obtained during the trials and real-world data on administering adults with Sputnik V.

Currently authorised in 71 countries, Sputnik V elicits a robust and durable immune response against Covid-19 compared to various other vaccines. 

According to a comparative study carried out at Lazzaro Spallanzani National Institute for Infectious Diseases in Italy, Sputnik V was found to offer over two times increased virus neutralising antibody titers against Omicron variant versus two-dose regimen with Pfizer’s Covid-19 vaccine.

Data from various studies showed that Sputnik V offers a robust immune response against the Omicron variant of the SARS-CoV-2 virus.

This response can be further enhanced by boosting with one dose Sputnik Light vaccine.

Earlier this month, the Drug Controller General of India granted authorisation to Sputnik Light against Covid-19.